Gensco® Pharma, in partnership with IntelGenx announced the anticipated launch of RizaFilm® for Q1-2024. RizaFilm® is based on IntelGenx's proprietary VersaFilm® technology and is patent protected until 2034. As the NDA holder, Gensco® will begin commercialization of the 10mg Film and will continue to fund the expanded indications for the 5mg Pediatric dose.

RizaFilm® is a film formulation of rizatriptan and the only oral dissolvable film available for the treatment of acute migraines. RizaFilm® has ease of convenience and does not require a drink for swallowing, thus allowing for rapid administration and relief from migraine related pain and nausea. The switch to RizaFilm® is seamless, as it is prescribed the same way as current rizatriptan, but in a Film form.

A patient survey indicated that 69% of respondents said they would discuss switching their current migraine therapy to RizaFilm® with their doctor. Patients are encouraged to discuss the benefits of switching to RizaFilm with their healthcare provider.